Daihong Liu

Company snapshot

Daihong Liu is a pharma organization headquartered in CN. Primary therapeutic focus areas include Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL). NovaPharmaNews links 1 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, and USPTO sources. Pipeline phase mix: phase 2 (1).

• 1 active pipeline program(s) linked via ClinicalTrials.gov.
• 1 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Daihong Liu. Not investment advice.

Recent activity

Latest pipeline, patent, and corporate events for Daihong Liu.

1. Jun 8, 2026 Clinical update

   CAR-T Cell Therapy + Chidamide and PD-1 Inhibitor Maintenance — Phase 2

View all clinical trial activity →

• What is Daihong Liu?

  Daihong Liu is a pharma organization headquartered in CN. Primary therapeutic focus areas include Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL). NovaPharmaNews links 1 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this entity from public FDA

• Is Daihong Liu publicly traded?

  Daihong Liu appears in our database through regulatory marketing authorisation or clinical trial sponsor records; a US listed ticker is not shown for this entity.

• What drugs does Daihong Liu develop or market?

  We link 8 drug profile(s) where Daihong Liu is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/daihong-liu#company-drugs.

• What are the latest developments for Daihong Liu?

  In the last 12 months our linked public records show 1 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Daihong Liu focus on?

  Daihong Liu focuses on Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL) based on our analysis of their pipeline programs and drug development activities.